A new generation of allergy treatments
Annual report 2014 for biggest biotech floatation in decades
Circassia's entry to the London Stock Exchange in 2014 was the biggest for any biotech for decades. The IPO valued the company at £581 million following a wave of biotech listings in the US in a year when the sector came back into favour with investors.
thinkerdoer was commissioned for our expertise in the sector and our experience of producing message driven annual reports. We focused our efforts on setting out the stall for Circassia and thier new generation of allergy treatments; the serious global health issue, the inadequate current available treatments, and the huge market opportunity.